Blue Trust Inc. Has $46,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)

Blue Trust Inc. boosted its position in NeoGenomics, Inc. (NASDAQ:NEO) by 42.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 3,318 shares of the medical research company’s stock after buying an additional 987 shares during the quarter. Blue Trust Inc.’s holdings in NeoGenomics were worth $46,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in NEO. Canada Pension Plan Investment Board bought a new position in NeoGenomics during the second quarter worth about $57,000. PNC Financial Services Group Inc. boosted its stake in shares of NeoGenomics by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,791 shares during the period. Banque Cantonale Vaudoise boosted its stake in NeoGenomics by 10.2% in the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 1,633 shares during the period. Gabelli Funds LLC bought a new stake in NeoGenomics in the 1st quarter valued at $283,000. Finally, SG Americas Securities LLC bought a new stake in shares of NeoGenomics during the 3rd quarter valued at $312,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NEO opened at $14.00 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -22.58 and a beta of 1.19. The stock has a 50 day moving average of $14.80 and a 200 day moving average of $14.70. NeoGenomics, Inc. has a 12 month low of $12.77 and a 12 month high of $21.22.

Analyst Ratings Changes

NEO has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a report on Wednesday, September 25th. Stephens restated an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Benchmark reiterated a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.